CX1739 | CAS#1086377-48-1 | Low-impact ampakine

MedKoo Cat#: 463817 | Name: CX1739

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CX1739 is a next-generation low-impact ampakine, meaning it positively modulates AMPA receptors without causing excessive excitotoxicity. It enhances glutamatergic neurotransmission by prolonging AMPA receptor-mediated currents, leading to increased synaptic plasticity and cognitive function while maintaining a favorable safety profile. it improves memory, learning, and attention, showing potential for neurodegenerative and cognitive disorders. It Has been investigated for counteracting opioid-induced respiratory depression and central sleep apnea by enhancing excitatory drive to respiratory neurons. Unlike high-impact ampakines, CX1739 does not induce excitotoxicity, making it a promising candidate for neurodegenerative diseases such as Alzheimer's or Parkinson’s.

Chemical Structure

CX1739

CAS#1086377-48-1

Theoretical Analysis

MedKoo Cat#: 463817

Name: CX1739

CAS#: 1086377-48-1

Chemical Formula: C13H15N3O3

Exact Mass: 261.1113

Molecular Weight: 261.28

Elemental Analysis: C, 59.76; H, 5.79; N, 16.08; O, 18.37

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

CX1739; CX 1739; CX-1739;

IUPAC/Chemical Name

N-methyl-N-(tetrahydro-2H-pyran-4-yl)benzo[c][1,2,5]oxadiazole-5-carboxamide

InChi Key

IRYRMRDDVXULFG-UHFFFAOYSA-N

InChi Code

InChI=1S/C13H15N3O3/c1-16(10-4-6-18-7-5-10)13(17)9-2-3-11-12(8-9)15-19-14-11/h2-3,8,10H,4-7H2,1H3

SMILES Code

O=C(C1=CC2=NON=C2C=C1)N(C)C3CCOCC3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 261.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Radin DP, Lippa A, Rana S, Fuller DD, Smith JL, Cerne R, Witkin JM. Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to today. Pharmacol Biochem Behav. 2025 Jan 31;248:173967. doi: 10.1016/j.pbb.2025.173967. Epub ahead of print. PMID: 39894310. 2: Radin DP, Zhong S, Cerne R, Witkin JM, Lippa A. High Impact AMPAkines Induce a Gq-Protein Coupled Endoplasmic Calcium Release in Cortical Neurons: A Possible Mechanism for Explaining the Toxicity of High Impact AMPAkines. Synapse. 2024 Sep;78(5):e22310. doi: 10.1002/syn.22310. PMID: 39304968. 3: Radin DP, Cerne R, Witkin JM, Lippa A. Safety, Tolerability, and Pharmacokinetic Profile of the Low-Impact Ampakine CX1739 in Young Healthy Volunteers. Clin Pharmacol Drug Dev. 2025 Jan;14(1):50-58. doi: 10.1002/cpdd.1475. Epub 2024 Sep 20. PMID: 39302241. 4: Witkin JM, Radin DP, Rana S, Fuller DD, Fusco AF, Demers JC, Pradeep Thakre P, Smith JL, Lippa A, Cerne R. AMPA receptors play an important role in the biological consequences of spinal cord injury: Implications for AMPA receptor modulators for therapeutic benefit. Biochem Pharmacol. 2024 Oct;228:116302. doi: 10.1016/j.bcp.2024.116302. Epub 2024 May 18. PMID: 38763261. 5: Rana S, Alom F, Martinez RC, Fuller DD, Mickle AD. Acute ampakines increase voiding function and coordination in a rat model of SCI. Elife. 2024 Mar 7;12:RP89767. doi: 10.7554/eLife.89767. PMID: 38451184; PMCID: PMC10962400. 6: Lomeli N, Pearre DC, Cruz M, Di K, Ricks-Oddie JL, Bota DA. Cisplatin induces BDNF downregulation in middle-aged female rat model while BDNF enhancement attenuates cisplatin neurotoxicity. Exp Neurol. 2024 May;375:114717. doi: 10.1016/j.expneurol.2024.114717. Epub 2024 Feb 8. PMID: 38336286; PMCID: PMC11087041. 7: Lomeli N, Pearre DC, Cruz M, Di K, Bota DA. Cisplatin Induces BDNF Downregulation in Middle-Aged Female Rat Model while BDNF Enhancement Attenuates Cisplatin Neurotoxicity. bioRxiv [Preprint]. 2023 May 17:2023.05.15.540850. doi: 10.1101/2023.05.15.540850. Update in: Exp Neurol. 2024 May;375:114717. doi: 10.1016/j.expneurol.2024.114717. PMID: 37293048; PMCID: PMC10245559. 8: Rana S, Alom F, Martinez RC, Fuller DD, Mickle AD. Acute ampakines increase voiding function and coordination in a rat model of SCI. bioRxiv [Preprint]. 2023 Nov 17:2023.05.26.542339. doi: 10.1101/2023.05.26.542339. Update in: Elife. 2024 Mar 07;12:RP89767. doi: 10.7554/eLife.89767. PMID: 37293023; PMCID: PMC10245998. 9: Rana S, Sunshine MD, Greer JJ, Fuller DD. Ampakines Stimulate Diaphragm Activity after Spinal Cord Injury. J Neurotrauma. 2021 Dec;38(24):3467-3482. doi: 10.1089/neu.2021.0301. PMID: 34806433; PMCID: PMC8713281. 10: Xiao D, Xie F, Xu X, Zhou X. The impact and mechanism of ampakine CX1739 on protection against respiratory depression in rats. Future Med Chem. 2020 Dec;12(23):2093-2104. doi: 10.4155/fmc-2020-0256. Epub 2020 Oct 8. PMID: 33030058. 11: Wollman LB, Streeter KA, Fuller DD. Ampakine pretreatment enables a single brief hypoxic episode to evoke phrenic motor facilitation. J Neurophysiol. 2020 Mar 1;123(3):993-1003. doi: 10.1152/jn.00708.2019. Epub 2020 Jan 15. PMID: 31940229; PMCID: PMC7099472. 12: Radin DP, Purcell R, Lippa AS. Oncolytic Properties of Ampakines In Vitro. Anticancer Res. 2018 Jan;38(1):265-269. doi: 10.21873/anticanres.12217. PMID: 29277782. 13: Ren J, Ding X, Greer JJ. Ampakines enhance weak endogenous respiratory drive and alleviate apnea in perinatal rats. Am J Respir Crit Care Med. 2015 Mar 15;191(6):704-10. doi: 10.1164/rccm.201410-1898OC. PMID: 25594679. 14: Silverman JL, Oliver CF, Karras MN, Gastrell PT, Crawley JN. AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology. 2013 Jan;64(1):268-82. doi: 10.1016/j.neuropharm.2012.07.013. Epub 2012 Jul 16. PMID: 22801296; PMCID: PMC3445667.